ESTRO 2023 - Abstract Book

S34

Saturday 13 May

ESTRO 2023

Figure 1 Survival curves, in months, from the time of radiotherapy with numbers at risk. a) Overall survival; median 7.9 months. b) Progression free survival; median 7.5 months. Conclusion This study, utilising hypofractionated radiotherapy (25Gy in 5 fractions), targeting the small volume macroscopic disease, utilising PTV margins appropriate for modern IGRT and VMAT techniques, has generated practice changing results commensurate with the literature. There were minimal side effects reported, suggesting this is a safe and feasible technique and further dose escalation should be investigated in prospective studies to achieve longer locoregional control. We conclude that even frail patients with incurable head and neck cancer can benefit from a short course of highly conformal radiotherapy to the gross target volume to stabilise and decrease disease related symptoms. PD-0067 How Our Patients Are. Patient-Reported Quality Of Life. C. Garcia Torres 1 , P.M. Samper Ots 2 , S. Payano Hernández 3 , J. Zapatero Ortuño 3 , E. Amaya Escobar 4 , M.D. de las Peñas Cabrera 5 , J. Rodríguez de la Peña 3 , C. Chaves Pantoja 6 , M. Martin López 6 , J. Gutierrez Loa 6 1 Rey Juan Carlos Hospital, Radiation Oncology, Móstoles- Madrid, Spain; 2 Rey Juan Carlos Hospital , Radiation Oncology, Móstoles- Madrid, Spain; 3 Rey Juan Carlos Hospital , Radiation oncology , Móstoles- Madrid, Spain; 4 Rey Juan Carlos Hospital , Radiation oncology , Móstoles- Madrid, Spain; 5 Rey Juan Carlos Hospital , Radiation oncology, Móstoles- Madrid, Spain; 6 Rey Juan Carlos Hospital, Radiation oncology, Móstoles- Madrid, Spain Purpose or Objective To analyse the impact on quality of life (Q&L) of oncology treatments. To know how patients are before and after radiotherapy. To assess which factors influence or are also related to a change in the quality of life of the oncological patient. Materials and Methods Prospective observational study on quality of life in oncology patients undergoing radiotherapy treatment. Patients referred to RT completed a PRO (patient reported outcomes), the EORTC Q&L questionnaire QLQ_C30 (assesses symptoms, quality of life and function) before starting RT and at the end of the treatment. Prognostic factors of baseline Q&L and the impact of treatment on Q&L were analysed. Only patients who were candidates for non-palliative radiotherapy of the most prevalent pathologies were included: breast, prostate, digestive tract, head and neck and lung cancer Results A total of 618 patients were analysed, with a mean age of 65.5 years, whose characteristics are shown in Table1. The baseline and final QLQ_c30 scores are shown in Figure 1, relating both results according to oncological treatments. In relation to oncologic treatments, patients with previous treatments such as surgery or chemotherapy reported worse initial quality of life, with loss of social and role function and increased insomnia common to both. Fatigue and diarrhoea was higher in patients with prior chemotherapy and pain in post-surgical patients. As for neoadjuvant chemoradiotherapy, only diarrhoea was significantly higher. Patients with radical chemoradiotherapy had the greatest loss of quality of life in practically all the items evaluated. In addition to the treatment factors, differences were observed in baseline quality of life, by sex, age range, smoking, and comorbidities such as hypertension, diabetes or dyslipidaemia.